Fibrinolysis in Intermediate-Risk PE Between Prevention and Risk – Unidad de ETV Hospital Gregorio Marañón
Unidad de ETV Hospital Gregorio Marañón shared a post on X about a recent article by Eva Cervilla-Muñoz et al., published in Journal of Clinical Medicine:
“The use of systemic fibrinolysis in intermediate-risk PE remains one of the great clinical debates: Prevent hemodynamic deterioration or assume greater hemorrhagic risk?
In our new article, conducted together with CardioHGUGM, we analyze a real-world cohort.”
Title: Systemic Fibrinolysis in Symptomatic Intermediate-Risk Pulmonary Embolism: A Real-World Cohort Study
Authors: Eva Cervilla-Muñoz, Pablo Demelo-Rodríguez, Rubén Alonso-Beato, Miriam Juárez-Fernández, Iago Sousa-Casasnovas, Lucía Ordieres-Ortega, Marina López-Rubio, Luis-Antonio Alvarez-Sala Walther, Francisco Galeano-Valle

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 17, 2026, 15:26Hereditary Hemorrhagic Telangiectasia: The Molecular Connection Between Vascular Malformations and Bleeding
-
Nov 17, 2026, 14:54Cindy Neunert: Beyond Platelet Counts – Addressing Fatigue and Whole-Person Care in ITP
-
Nov 17, 2026, 14:44Strengthening Haemophilia Diagnosis Through Hands-On Laboratory Training – IAHAD
-
Nov 17, 2026, 14:40Platelet Membrane Protrusions Beyond Their Role in Hemostasis – JTH
-
Nov 17, 2026, 14:10Wolfgang Miesbach: Aspirin vs Anticoagulants – Who Needs More Than Aspirin?
-
Nov 17, 2026, 14:08Chaza Alaji: Soluble Transferrin Receptor – A Key to Uncovering Hidden Iron Deficiency
-
Nov 17, 2026, 14:03Shadi Tabibian: Fibrinogen – From Molecular Structure to Clinical Decision Making
-
Nov 17, 2026, 13:54Gabrielle Sarlon: Breaking the Silence on Menstrual Bleeding During Anticoagulant Therapy
-
Nov 17, 2026, 13:47Ksenia Guznova Kats: Advanced Venous Stenting in May–Thurner Syndrome